Bedside-to-bench investigation in the β-hemoglobinopathies has pioneered insights into fundamental mechanisms in biology (eg, coordinated, consecutive activation of a gene series). These discoveries have opened the door to rational, noncytotoxic methods of manipulating cell fates and functions (eg, by inhibiting corepressors) for the therapy mission in the β-hemoglobinopathies and beyond.